Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte R, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44.

Article  CAS  PubMed  Google Scholar 

Vyas A, Raval AD, Kamat S, LaPlante K, Tang Y, Chemaly RF. Real-world outcomes associated with letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies. Open Forum Infect Dis. 2022;10:ofac687.

Article  PubMed  PubMed Central  Google Scholar 

Cassaniti I, Colombo AA, Bernasconi P, Malagola M, Russo D, Iori AP, et al. Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. Am J Transplant. 2021;21:1622–28.

Article  CAS  PubMed  Google Scholar 

Solano C, Giménez E, Albert E, Piñana JL, Navarro D. Immunovirology of cytomegalovirus infection in allogeneic stem cell transplant recipients undergoing prophylaxis with letermovir: a narrative review. J Med Virol. 2023;95:e29005.

Article  CAS  PubMed  Google Scholar 

Giménez E, Guerreiro M, Torres I, Aguilar C, Albert E, Hernández-Boluda JC, et al. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir. Transpl Infect Dis. 2023;25:e1402.

Article  Google Scholar 

Solano C, Giménez E, Piñana JL, Vinuesa V, Poujois S, Zaragoza S, et al. Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood. Bone Marrow Transplant. 2016;51:718–22.

Article  CAS  PubMed  Google Scholar 

Huntley D, Talaya A, Giménez E, Martínez A, Hernández-Boluda JC, Hernani R, et al. Features of cytomegalovirus DNAemia Blips in allogeneic hematopoietic stem cell transplant recipients: implications for optimization of preemptive antiviral therapy strategies. Biol Blood Marrow Transplant. 2020;26:972–7.

Article  CAS  PubMed  Google Scholar 

Zamora D, Duke ER, Xie H, Edmison BC, Akoto B, Kiener R, et al. Cytomegalovirus‐specific T‐cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood. 2021;138:34–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gabanti E, Borsani O, Colombo AA, Zavaglio F, Binaschi L, Caldera D, et al. Human cytomegalovirus‐specific T‐cell reconstitution and late‐onset cytomegalovirus infection in hematopoietic stem cell transplantation recipients following letermovir prophylaxis. Transplant Cell Therapy. 2022;28:211.e1–211.e9.

Article  CAS  Google Scholar 

Lauruschkat CD, Muchsin I, Rein A, Erhard F, Grathwohl D, Dölken L, et al. CD4+T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis. Front Immunol. 2023;14:1148841.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zavaglio F, Vitello D, Bergami F, Arena F, Borsani O, Colombo AA, et al. Human Cytomegalovirus (HCMV)-specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients. J Clin Virol. 2023;165:105519.

Article  CAS  PubMed  Google Scholar 

Lauruschkat CD, Muchsin I, Rein AF, Erhard F, Grathwohl D, Dölken L, et al. Impaired T and “memory-like” NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation. Blood Adv. 2024;8:2967–79.